• 대한화학회지
• /
• 제40권4호
• /
• pp.243-248
• /
• 1996

Cyclopentadecanone(2)으로부터 2-cyclopentadecen-1-one(4)까지의 일반적인 합성경로는 여러가지가 있을 수 있다. 본 실험에서는 우선 $C_2$-위치의 선택적인 브롬화반응을 위하여 $AlCl_3$를 써서 엔올산 염화하여 위치선택성을 증가시켰으며, 브롬화 수소 이탈반응에서의 시약 $Li_2CO_3$-LiBr-DMF 조건을 적절히 조절함으로써 화합물(4)를 쉽게 얻을 수 있었다. 이 과정에서 생기는 트랜스형 및 시스형 화합물(4)를 E.Ether 용매속에서 $CH_3MgI-Cu_2Cl_2$ 복합체에 적하하여 반응시킬 경우, 모두 1,4-첨가반응되어 dl-Muscone(1)를 생성함을 결과로 얻었다. 본 실험에서 Cyclopentadecanone(2)으로부터 dl-Muscone(1)까지의 3단계 과정을 통해 순수한 dl-Muscone(1)을 총 85%의 높은 수율로 얻었으며, 별다른 화학적 분리단계를 거치지 않아, 합성단가를 기존의 어느 방법보다 현격히 낮출수 있었다.

• Toxicological Research
• /
• 제14권2호
• /
• pp.237-248
• /
• 1998

The acute and subacute toxicity of New Woohwangchungsimwon(NWCH) which was used l-muscone as substitutive material of musk were investigated in S.D. rats. In intraperitoneal acute toxicity test. rats(Sprague-Dawley, SPF) were injected intraperitoneally with dosages of 0, 540, 750, 1,070, 1.500 and 3,000 mg/kg. Body weights were significantly decreased at 540 mg/kg dose group in both sexes and abnormal autopsy findings were founded in both sexes at all treated groups. Intraperitoneal $LD_{50}$ of NWCH was 812.3 mg/kg in male and 872.3 mg/kg in female rats. In the subacute toxicity study, NWCH was administrated orally to both sexes of rats for 4 weeks as several doses(0, 320, 800 and 2, 000 mg/kg). There were neither dead animals nor significant changes of body weights during the experimental period. In addition, no differences were found between control and treated groups in clinical signs, urinalysis, hematology, serum biochemical analysis, and other findings. Above data strongly suggest that no observed adverse effect level of NWCH might be over 2,000 mg/kg/day in this study.

• Toxicological Research
• /
• 제14권2호
• /
• pp.249-260
• /
• 1998

Single and 4 weeks oral administration of New Woohwangchungsimwon (NWCH) which was used l-muscone as substitutive material of musk, to beagle dogs of both sexes were performed to investigate both acute and subacute toxicity. Beagle dogs(3 males and 3 females) in acute experiments were administered orally with single dose of 2,000 mg/kg and groups of 9 male and 9 female beagle dogs in subacute experiments were given daily different dosage of NWCH, 160 mg/kg/day (low dosage group), 400 mg/kg/day (middle dosage group), 1,000 mg/kg/day (high dosage group) once a day for 4 weeks by oral route according to the Established Regulation of Korea Food and Drug Administration (1996. 4. 16). $LD_{50}$/ value for beagle dogs was more than 2,000 mg/kg per oral for both male and fe-males. In animals administered with NWCH, there were neither dead animals nor significant changes of body weights. In addition, no differences were found between control and treated groups in clinical sign, urinalysis, eye examination, hematology, serum chemistry, organ weight and other fingings. No histological lesions were observed in both control and treatment groups. Above data strongly suggset that NWCH in beagle dogs is considered to be safe.